Focus Area

Research & Science

The world is running low on new antibiotics, and the market is to blame.

Why the Antibiotic Pipeline Keeps Thinning

Payment systems still reward the volume of antibiotics sold rather than their value to society, so companies cannot sustain the investment that new medicines require, and the pipeline keeps thinning. The scientific workforce is thinning, too.

By the numbers

A Shrinking Workforce, a Steady Investment

01

~ 0

researchers identified working on AMR

02

~ 0

researchers working on cancer, by comparison

03

$ 0 billion

invested by Alliance members in AMR research and development each year

Sources: AMR Industry Alliance, Leaving the Lab, 2024; RAND Europe / AMR Industry Alliance Progress Survey.

Our Response

Rebuilding the Pipeline

Alliance members invest around $2 billion in AMR research and development each year, evidence that the private sector continues to invest even where incentives fall short.

We track the scale of the decline and support the pull incentives and de-linked payment models, such as subscription-style purchasing, that would reward responsible supply and rebuild the pipeline.

Featured Report

Leaving the Lab

An analysis of the scientific workforce working on antimicrobial resistance.

Resources

Explore Research & Science Resources

Access research, reports, and news on antimicrobial innovation and the scientific workforce working to address antimicrobial resistance.

Report

Leaving the Lab

News

A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease Clinicians

News

Vanishing Workforce: An Antimicrobial Resistance Threat

News

What Happens When the Last AMR Researcher Turns Off the Lights in the Lab?

News

NHS launches ‘subscription’ scheme for antibiotics with pharma sector

News

Antibiotic innovation is ailing. ‘Brain drain’ may kill it

Get in touch

Whether you’re a member, a partner, or exploring how to engage,
we’d like to hear from you.